Published in AIDS Weekly, June 27th, 2005
Bristol-Myers Squibb's Reyataz is the first once-daily protease inhibitor that also has a favorable lipid side-effect profile. Gilead's Truvada is a highly potent, well-tolerated, convenient, once-daily fixed-dose combination of 2 non-nucleoside reverse transcriptase inhibitors. Increased uptake of both products will drive overall sales growth in the near term. In the longer term, classes with novel mechanisms of action will expand the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.